ASCO 2023

ADC revolution: How can the new results be integrated…

Discussions and controversies on social-media: what is…

CDK4/6i in EBC: Have abema and ribo arrived in the…

CDK4/6 inhibitors in EBC: Amazing data, but longer…

PART2: Trying to understand optimal therapy for…

PART1: How to de-escalate chemotherapy? What is the…

New data on Ribocilib in adjuvant setting EBC: What…

Data from Meta-Analyses of almost 15k Patients: Who…

TILs are prognostic but not predictive in HER2+ EBC

TILs in HER2+ disease - prognostic, but not enough to…

Ribociclib improves iDFS

Young patients benefit from ovarian suppression

TILs subtypes are associated with clinical features and…

First data with adjuvant ribociclib

Early follow-up shows clear benefit

SOC of ovarian ablation confirmed in meta-analysis.

More CDK4/6 options for EBC patients

Checkpoint inhibition in endometrial cancer: new…

My EBC highlights from ASCO23

1/3 of patients with HER2+ in future without…

10 years update on ShortHER

Another proof of efficacy of immunotherapy in advanced…

Response adapted, chemotherapy-free option in HER2+ EBC

Ribociclib has arrived in the adjuvant setting

Chemo-immunotherapeutic signals especially in HER2low…

Tumor-informed ctDNA likely prognostic for relapse in…

A challenge for clinical management

Ovarian function - Ovarian suppression not necessary in…

White blood cells with increasing prognostic relevance?…

From PENELOPE-B to SURVIVE

De-escalation of CT for early BC

Can we preserve our patients form chemotherapy?

PHERGain opens the possibility to avoid chemotherapy in…

Analyses of ctDNA in PENELOPE-B: Test methods are…

Practice changing or not quite yet?

Palbociclib after Palbociclib might not be the best…

Kolejny dowód na skuteczność immunoterapii w…

Von PENELOPE-B zur SURVIVE

1/3 der Patientinnen mit HER2+ zukünftig ohne…

Eine Herausforderung für viele Patienten, wenig…

I miei punti salienti di ASCO23

Palbociclib después de Palbociclib podría no ser la…

Ovar Funktion - Ovarielle Supression verzichtbar bei…

NATALEE nicht überraschend aber überzeugend positiv

Primele date cu ribociclib adjuvant

Chemo-IO Signale bei HER2low prädiktiv für Ansprechen…

TILs Subtypen sind assoziiert mit klinischen Merkmalen…

Eine Herausforderung für das klinische Management

PHERGain abre la posibilidad de evitar la quimioterapia…

Tumor-informed ctDNA wahrscheinlich prognostisch für…

TILs w rakach HER2+ - znaczenie rokownicze, ale nie…

SOC der ovarialen Ablation in der Metaanalyse bestätigt

TILs sind prognostisch aber nicht prädiktiv beim HER2+…

Response adaptierte, Chemotherapie-freie Option beim…

CDK4/6 i beyond CDK4/6 i: one more piece to the puzzle

The start of precision medicine in HR+ breast cancer

Molecular imaging for endocrine responsivness

Continued OS benefit for Sacituzumab Govitecan

Updates on ADCs in metastatic breast cancer

E-Health Applications in Oral Cancer Therapy

Mises à jour sur les ADC dans le cancer du sein…

CDK4/6i dopo CDK4/6i, un altro pezzo del puzzle: lo…

CDK4/6i in first line and beyond & Biomarkers

The value of eHealth

CDK4/6 Sequencing? ESR-1 not ready for prime time?…

Part 1: Important update on testosterone-recovery

Metastasis-directed for prostate cancer

PAPR-inhibitors: Patient-selection matters!

AI for prediction in local prostate carcinoma

PEACE 1 - results and controversies

PSA nadir 6 month after Radiotherapy is strong…

Confirming results for PARPi in mCRPC

Reassuring real-world data!

Over-staging of bone scan compared with PSMA PET/CT

DEAR trial: real-world comparator analyses of ARIs

ARASEC: ADT + Daralutamide for mHSPC

Intensified or de-intensified therapy in mHSPC

TALAPRO-2: Results and controversies

Part2: Important update on testosterone-recovery

PRL-02: Intramuscular arbiraterone

LuPARP studien: 177-Lu-PSMA och olaparib vid mCRPC

Skelettscintigrafi ospecifikt jämfört med PSMA PET-CT

PSA nadir 6 månader efter radioterapi är en prognostisk…

PARP-inhibitors: La selección de pacientes es…

Επιβεβαίωση αποτελεσμάτων για το PARPi στο mCRPC

What is your preferred sequence in 1st line treatment…

PARPi in PCa: more genetic testing is required as PRO…

Q-TWiST in the therapy of aUC

Best of Bladder: ddMVC increases DFS! Standard…

Enfortumab vedotin + pembrolizumab 1stL in…

New standard for MIBC

FGFR inhibition

Targeted therapies in advanced urothelial cancer: The…

First line in cisplatin-ineligible advance urothelial…

Extent of lymphadenectomy in cystectomy

New SoC option for metastatic bladder cancer

Best of Bladder: ddMVC increases DFS! Standard…

Primera línea en cáncer urotelial avanzado no elegible…

Nouvelles options de soins standard pour le cancer de…

The efficacy of neo-adjuvant therapy (ddMVAC,…

The efficacy of FGFR targeting

Non ccRCC: how should we treat patients today?

Long term follow up in advanced renal cell cancer: Is…

Primary endpoint not reached: what do we learn from…

Update and take home message of 1st Line mRCC

New data non ccRCC

1st Line therapy RCC: which combination to choose?

New standard for 2nd line RCC?

Long-term follow-up for IO/TKI in mRCC

Lenvatinib + pembrolizumab in non-clear cell renal cell…

IO rechallenge in mRCC

The value of perioperative chemo-IO in rNSCLC and the…

ADAURA - Discussion closed?

A chemo-free preop. IO strategy?

More options in the perioperative setting

Confirmation of neoadjuvant immunotherapy

Which should we prefer: neoadjuvant, adjuvant or…

Added benefit of perioperative chemo/IO in stage 2-3b…

Adjuvant IO in KRASm patients

Perioperative treatment

Adjuvant and neoadjuvant strategies in resectable NSCLC

A new standard of care for operated patients with…

Another neoadjuvant chemo/IO option

Role of periopertative IO confirmed

ADAURA - results and controversies

EGFR testing necessary in the adjuvant setting

CheckMate 9LA: 4‑year clinical update

OS benefit from EGFR receptor TKI

A new standard of care

Induction options in the perioperative setting

Toegevoegde waarde van periperatief chemo-immuno bij…

Más opciones en el entorno perioperatorio

Que devrions-nous préférer: traitement néoadjuvant,…

Un nouveau standard therapeutique pour les patients…

ADAURA- discussie gesloten?

Rolle der periopertativen IO bestätigt

Does ADC + chemo + IO replace the existing concepts?

Pembro + chemo in pts with TKI-resistant EGFRm /…

Update on KRASG12Cm treatment options - how to proceed?

TTF-treatment requires further studies

Zorifertinib: an option when osimertinib is not…

Stopping treatment is ok

LUNAR: TTF medical device shows OS-benefit, but more…

ADC + ICI ± Pt-CT in patients with aNSCLC

IO in EGRF positive patients post TKI

CORRELATE - a real world analysis

New data from another BiTE

More BiTEs, more possibilities

Can we incoporate biomarkers in SCLC treatment?

A positive trial with no impact

Treatment strategies in SCLC

Kunnen we biomarkers gebruiken om behandeling te…

Stratégies de traitement dans le SCLC

Immune checkpoint inhibitors in malignant mesothelioma

No practice-changing data in mesothelioma, other…